User menu

Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen.

Bibliographic reference Osselaer, Jean-Claude ; Debry, Cécile ; Goffaux, Maite ; Pineau, Jacqueline ; Calomme, Genevieve ; et. al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen.. In: Transfusion, Vol. 48, no. 1, p. 108-17 (2008)
Permanent URL http://hdl.handle.net/2078.1/11129
  1. Williamson Lorna M., Cardigan Rebecca, Prowse Chris V., Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?, 10.1046/j.1537-2995.2003.00483.x
  2. Lin L, Transfusion, 44, L (2004)
  3. Lin Lily, Hanson Carl V., Alter Harvey J., Jauvin Valérie, Bernard Kristen A., Murthy Krishna K., Metzel Peyton, Corash Laurence, Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light, 10.1111/j.0041-1132.2005.04316.x
  4. Wollowitz Susan, Fundamentals of the psoralen-based Helinx[trade ] technology for inactivation of infectious pathogens and leukocytes in platelets and plasma, 10.1053/shem.2001.29495
  5. Singh Yasmin, Sawyer Lynette S., Pinkoski Linda S., Dupuis Kent W., Hsu Jocelyn C., Lin Lily, Corash Laurence, Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function, 10.1111/j.1537-2995.2006.00867.x
  6. Müller-Breitkreutz Konstanze, Mohr Harald, Briviba Karlis, Sies Helmut, Inactivation of viruses by chemically and photochemically generated singlet molecular oxygen, 10.1016/1011-1344(95)07150-z
  7. Lin Lily, Conlan Maureen G., Tessman John, Cimino George, Porter Seth, Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment, 10.1111/j.1537-2995.2005.00554.x
  8. Van Voorhis W. C., Barrett L. K., Eastman R. T., Alfonso R., Dupuis K., Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV, 10.1128/aac.47.2.475-479.2003
  9. Eastman Richard T., Barrett Lynn K., Dupuis Kent, Buckner Frederick S., Van Voorhis Wesley C., Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation, 10.1111/j.1537-2995.2005.00552.x
  10. Castro E, Vox Sang, 91, 176 (2006)
  11. Gironés N., Bueno J. L., Carrión J., Fresno M., Castro E., The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma, 10.1111/j.1423-0410.2006.00840.x
  12. Wagner SJ, Robinette D, Storry J, Chen XY, Shumaker J, Benade L, Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization, 10.1046/j.1537-2995.1994.34694295069.x
  13. Aznar J.A., Molina R., Montoro J.M., Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma, 10.1046/j.1537-2995.1999.39070748.x
  14. Garwood Margaret, Cardigan Rebecca A., Drummond Olive, Hornsey Valerie, Turner Craig P., Young David, Williamson Lorna M., Prowse Chris V., The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma, 10.1046/j.1537-2995.2003.00485.x
  15. Hornsey V. S., Drummond O., Young D., Docherty A., Prowse C. V., A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system, 10.1046/j.1365-3148.2001.00282.x
  16. Beeck H., Hellstern P., In Vitro Characterization of Solvent/Detergent-Treated Human Plasma and of Quarantine Fresh Frozen Plasma, 10.1111/j.1423-0410.1998.tb05476.x
  17. Heiden Margarethe, Seitz Rainer, Quality of therapeutic plasma—requirements for marketing authorization, 10.1016/s0049-3848(02)00152-4
  18. Solheim Bjarte G., Hellstern Peter, Composition, efficacy, and safety of S/D-treated plasma : LETTERS TO THE EDITOR, 10.1046/j.1537-2995.2003.00461.x
  19. 19. KJ Beach . Important prescribing information [monograph on the Internet]. Watertown (MA): V.I. Technologies, Inc. (VITEX); 2000 . Available from: http://www.fda.gov/medwatch/safety/2000/plassd.pdf
  20. Flamholz Rachel, Jeon Hye-Ran, Baron Joseph M., Baron Beverly W., Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses?, 10.1002/1098-1101(2000)15:3<169::aid-jca2>3.0.co;2-r
  21. Yarranton Helen, Cohen Hannah, Pavord Sue R., Benjamin Sylvia, Hagger Diana, Machin Samuel J., Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura, 10.1046/j.1365-2141.2003.04360.x
  22. Pock K, Thrombin generation capacity is significantly impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a pharmaceutically licensed coagulation active plasma (Octaplas), and a development product (Uniplas) [abstract].
  23. Politis C, Vox Sang, 92, 319 (2007)
  24. Alvarez-Larran A., Del Rio J., Ramirez C., Albo C., Pena F., Campos A., Cid J., Muncunill J., Sastre J.-L., Sanz C., Pereira A., Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura, 10.1111/j.0042-9007.2004.00506.x
  25. de la Rubia Javier, Arriaga Francisco, Linares Dolores, Larrea Luis, Carpio Nelly, Marty Maria L., Sanz Miguel A., Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura, 10.1046/j.1365-2141.2001.02991.x
  26. Atance Rosa, Pereira Arturo, Ramirez Begona, Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate, 10.1046/j.1537-2995.2001.41121548.x
  27. de Alarcon P, Transfusion, 45, 1362 (2005)
  28. Mintz P. D., Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease, 10.1182/blood-2004-03-0930
  29. Mintz Paul D., Neff Anne, MacKenzie Malcolm, Goodnough Lawrence T., Hillyer Christopher, Kessler Craig, McCrae Keith, Menitove Jay E., Skikne Barry S., Damon Lloyd, Lopez-Plaza Ileana, Rouault Charles, Crookston Kendall P., Benjamin Richard J., George James, Lin Jin-Sying, Corash Laurence, Conlan Maureen G., A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura : AMOTOSALEN-TREATED FFP IN TTP, 10.1111/j.1537-2995.2006.00959.x
  30. Ciaravino V., McCullough T., Cimino G., Sullivan T., Preclinical safety profile of plasma prepared using the INTERCEPT Blood System, 10.1046/j.1423-0410.2003.00351.x
  31. Ciaravino Vic, Preclinical safety of a nucleic acid-targeted helinx TM compound: A clinical perspective, 10.1016/s0037-1963(01)90119-2
  32. Wagner SJ, Cifone MA, Murli H, Dodd RY, Myhr B, Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation, 10.1046/j.1537-2995.1995.35595259151.x
  33. Hejtmancik M. R., Hematological Effects in F344 Rats and B6C3F1 Mice during the 13-Week Gavage Toxicity Study of Methylene Blue Trihydrate, 10.1093/toxsci/65.1.126